

TEOXANE



Effectiveness, safety, and routine use of TEOSYAL® PureSense Redensity 2 treatment in the periorbital region

Bárbara Magalhães*, Jimmy Faivre**, Manuel-Anthony Da Costa***, Kévin Poupard***, and Stefania Ballarini*

*Medical Affairs Department, Teoxane SA, Geneva, Switzerland

**R&D Department, Teoxane SA, Geneva, Switzerland

***Clinical Department, Teoxane SA, Geneva, Switzerland

✉ b.magalhaes@teoxane.com

🌐 <https://www.teoxane.com/>

📷 <https://www.instagram.com/teoxaneofficial/>



Bárbara Magalhães

Medical Affairs Department, Teoxane SA, Geneva, Switzerland

✉ b.magalhaes@teoxane.com

Jimmy Faivre

R&D Department, Teoxane SA, Geneva, Switzerland

✉ j.faivre@teoxane.com

Manuel-Anthony Da Costa

Clinical Department, Teoxane SA, Geneva, Switzerland

✉ ma-.dacosta@teoxane.com

Kévin Poupard

Clinical Department, Teoxane SA, Geneva, Switzerland

✉ k.poupard@teoxane.com

Stefania Ballarini

Medical Affairs Department, Teoxane SA, Geneva, Switzerland

✉ s.ballarini@teoxane.com



The appearance of the periorbital region is a frequent concern of patients seeking rejuvenation treatment




The periorbital area is essential in facial aesthetic perception¹ as it:

- plays a key role in conveying emotions through facial expressions²
- is the hallmark of the aging status and fatigue of the entire face^{1,3}



- **78.8%** of patients seeking minimally invasive procedures expressed interest in improving the appearance of their periorbital region⁴
- Hyaluronic acid (HA) dermal fillers have gained popularity as an effective, non-surgical alternative to improve the appearance of the periorbital region^{5,6}

Periorbital indications



TEOSYAL® PureSense Redensity 2

10-years

of use in clinical practice

for the correction of fine lines/wrinkles affecting a withered skin marked by signs of ageing, and the treatment of the under eyes circles, including the tear trough⁷⁻⁹

Clinically proven efficacy and safety in the tear trough^{8,9}

99%

of patients and physicians perceived an aesthetic improvement

75%

of patients reported no side effects

98%

of patients described marked or moderate satisfaction

Hyaluronic Acid (HA) concentration	15 mg/mL
Formula composition	Mix of crosslinked & noncrosslinked HA
Degree of Modification (MoD) BDDE crosslinking	5.5%
Lidocaine	0.3%
Supplemented* phosphate buffer pH 7.3	q.s. ad 1 mL
Packaging	2 x 1 mL
Needle	30G x 1/2"

High malleability and spreadability^{2,8-10}

Low strength, low rigidity, and low resistance to compression

Low hygroscopy^{2,8-10}


Combination of crosslinked and non-cross-linked HA, at a low HA concentration, allows for minimal water absorption → minimal swelling

Redensity 2 formulation and rheological properties make it the elective gel to evenly fill the under-eye circles, in particular the tear trough




Global Post-Market Surveillance (PMS) Surveys – Redensity 2¹¹⁻¹⁴

- Proactive **real-world evidence (RWE)** collection to support Post-Market Surveillance activities, such as the Post-Market Clinical Follow-up (PMCF) report
- PMS surveys gather **insights from worldwide practitioners** and highlight global uses and trends related to TEOSYAL[®] products
- Powerful tool to reinforce Teoxane's awareness on the **routine use, performance and safety** of TEOSYAL[®] products




2021¹⁴


Within the periorbital region, the **tear trough** represented most of the treatments with Redensity 2



Most practitioners reported a **performance duration of 6 to 18 months** in the tear trough



Good safety profile with low incidence of adverse events and no reported serious adverse events



- 1: Pain at the injection site/ Tenderness
- 2: Redness/ Erythema
- 3: Bruising/ Haematoma/ Ecchymosi/ Injection site bleeding
- 4: Immediate-transcient swelling/ Oedema




EYELIGHT registry – Redensity 2 for periorbital region treatment


A **prospective, observational registry** conducted in Europe with a similar study design to the GRADUAL registry^{15,16}

Objective: gather RWE to assess the **effectiveness, safety and routine use of TEOSYAL® PureSense Redensity 2** for aesthetic treatments, including treatments performed in the **periorbital area**

EYELIGHT study design





Demographic characteristics of the general population




Almost all injectors were satisfied with initial Redensity 2 treatment, and only 19% of the subjects required touch-ups



Number of initial injections per periorbital indication




Redensity 2 provided significant aesthetic improvement in the periorbital region



*Proportion of subjects deemed "improved" or "much improved" on the GAIS scale by principal investigator and subject, at 29-153 days post-treatment or directly after injection

Performance of Redensity 2 was demonstrated up to 9 months, and was still satisfactory at 12 months for 1/3 of the subjects



Proportion of subjects deemed "improved" or "much improved" on the GAIS scale by principal investigator and subject, at different timepoints






Most patients were satisfied and would recommend treatment with Redensity 2 in all periorbital indications


Subject Satisfaction* Subject Recommendation**

Results retrieved at 3 months; no data available for crow's feet



On average, **70%** of the subjects associated "**natural looking**" with their appearance after treatment, while **20%** used the word "**rejuvenated**"





Injection site pain

- Pain experienced by subjects after injection was deemed mild to moderate
- Pain intensity decreased drastically for all subjects by the end of consultation

Other common treatment reactions (CTRs)

- All CTRs reported by the investigator* immediately after injection were deemed mild or moderate
- Bruising and swelling were the most frequent CTRs

Adverse events

Only two subjects experienced device-related adverse events (filler migration and skin oedema); both complications were rated moderate and were resolved without sequelae

As observed with PMS survey findings, RWE from a prospective observational registry confirmed the good safety profile of Redensity 2 in the whole periorbital region



Conclusions


Redensity 2 is an HA-based dermal filler with specific properties that make it the **treatment of choice for the under-eye circles, including the tear trough**^{2,8-10}

Observational evidence^{11-14,15} confirmed the **tear trough as the main indication treated with Redensity 2**, but it also showed its use in **other periorbital indications**

Almost all injectors were **satisfied with initial treatment**, and most of the subjects required **only one treatment session with Redensity 2**

RWE analysis confirmed the **effectiveness¹⁵ and good safety profile^{11-14,15}** of Redensity 2 in both the **tear trough** and the remaining **periorbital indications**

Most of the patients were **satisfied with Redensity 2** and would **recommend this treatment in the periorbital region¹⁵**



Perspectives

Real world-evidence supports the efficacy, safety and the potential use of Redensity 2 to treat the whole periorbital region



References

1. Kashkouli MB, Abdolalizadeh P, Abolfathzadeh N, Sianati H, Sharepour M, Hadi Y. Periorbital facial rejuvenation; applied anatomy and pre-operative assessment. *J Curr Ophthalmol*. 2017 Apr 25;29(3):154-168
2. Anido J, Fernández JM, Genol I, Ribé N, Pérez Sevilla G. Recommendations for the treatment of tear trough deformity with cross-linked hyaluronic acid filler. *J Cosmet Dermatol*. 2021 Jan;20(1):6-17
3. Nguyen HT, Isaacowitz DM, Rubin PA. Age- and fatigue-related markers of human faces: an eye-tracking study. *Ophthalmology*. 2009 Feb;116(2):355-60
4. Sobanko JF, Taglienti AJ, Wilson AJ, Sarwer DB, Margolis DJ, Dai J, Percec I. Motivations for seeking minimally invasive cosmetic procedures in an academic outpatient setting. *Aesthet Surg J*. 2015 Nov;35(8):1014-20
5. Gorbea E, Kidwai S, Rosenberg J. Nonsurgical Tear Trough Volumization: A Systematic Review of Patient Satisfaction. *Aesthet Surg J*. 2021 Jul 14;41(8):NP1053-NP1060
6. Trinh LN, Grond SE, Gupta A. Dermal Fillers for Tear Trough Rejuvenation: A Systematic Review. *Facial Plast Surg*. 2022 Jun;38(3):228-239
7. TEOSYAL® PureSense Redensity 2 – Instructions For Use
8. Berguiga M, Galatoire O. Tear trough rejuvenation: a safety evaluation of the treatment by a semicrosslinked Hyaluronic Acid filler. *Orbit*, 2017; 36 (1):22-26.
9. Ardeleanu, Valeriu, Sorin Berbece, Ioan Petre Florescu and Radu Cristian Jecan. The Use of Hyaluronic Acid Combined with Teosyal Redensity II for the Treatment of Dark Circles Under the Eyes. *Materiale Plastice*. 2017 Mar; 54: 37-40.
10. TEOXANE R&D report. Data on File. Physical analysis of HA fillers intended for infraorbital uses
11. TEOXANE PMCF report 2018. Data on File
12. TEOXANE PMCF report 2019. Data on File
13. TEOXANE PMCF report 2020. Data on File
14. TEOXANE PMCF report 2021. Data on File
15. Bhojani-Lynch T, Deckers A, Ohanes O, Poupard K, Maffert P. A Prospective, Observational Registry Study to Evaluate Effectiveness and Safety of Hyaluronic Acid-Based Dermal Fillers in Routine Practice: Interim Analysis Results with One Year of Subject Follow-Up. *Clin Cosmet Investig Dermatol*. 2021 Nov 16;14:1685-1695
16. TEOXANE EYELIGHT CSR report. Data on file. Report on final statistical analysis results

